Basic fibroblast growth factor (bFGF) is a pleiotropic cytokine blebbing, cell shrinkage, chromatin condensation and fragwhich has recently been shown to delay fludarabine-induced mentation. 9 The proto-oncogene bcl-2, an inner mitochon- shown to occur infrequently in CLL. 
Introduction

Reagents
Basic fibroblast growth factor (bFGF) is a pleiotropic cytokine which plays an important role in angiogenesis and mesoderFludarabine des-phosphate (FAra, 9-␤-d-arabinosyl-2-mal development, 1 and it has been postulated to play a role fluoroadenine) (Sigma, St Louis, MO, USA) was dissolved in in malignancy. 2 In previous studies, increased levels of bFGF 100% dimethylsulfoxide (DMSO) for a stock solution of have been detected in urine from patients with a broad variety 10 mm. It was further diluted in medium at final concenof neoplastic diseases including various leukemias. 3, 4 Other trations of 1-100 m, respectively. Recombinant human basic investigators have demonstrated elevated levels of bFGF in fibroblast growth factor (bFGF) was purchased from R&D Syscells derived from renal cell carcinoma 5 and malignant melatems (Minneapolis, MN, USA) and diluted in medium. noma. 6 In addition, a correlation between increased levels of bFGF and impaired prognosis in these diseases has been established. 7 
Cells
Recently, we have been able to show, that intracellular protein levels of bFGF correlate with stage of disease in B cell
The well characterized human B cell leukemia cell lines JVMchronic lymphocytic leukemia (B-CLL) cells and that these 2 15, 17 and JVM-13 were established from the peripheral blood elevated levels are associated with enhanced survival of CLL of a patient with B-prolymphocytic leukemia by EBV translymphocytes upon treatment with fludarabine, a drug known formation, respectively. 16 The human chronic B cell leukemia to induce apoptosis in B-CLL cells. 8 cell line I83CLL was derived from the peripheral blood of a Apoptosis is an active process of programmed cell death patient with B cell chronic lymphocytic leukemia (B-CLL) by which occurs during the senescence of normal cells. It is EBV transformation. 18 The human EBV-negative chronic B cell characterized by morphological changes, such as membrane leukemia cell line WSU-CLL was established from a patient with advanced B-CLL. 19 All four cell lines were cultured in RPMI 1640, supplemented with 1% penicillin/streptomycin, Correspondence: A Kö nig, Memorial Sloan-Kettering Cancer Center, B (Tel-Test, Friendswood, TX, USA) per 10 6 cells. Chloroform (100 l/ml of lysate) was added to the samples and after vortexing, the suspension was incubated on ice for 5 min followed by centrifugation at 12 000 g at 4°C for 15 min. The aqueous phase was then transferred into a fresh tube and an equal volume of isopropanol was added. Samples were kept on ice for 60 min and centrifuged at 12 000 g at 4°C for 15 min. The pellets were washed with 75% ethanol, dried, and resuspended in H 2 O. RNA concentration was determined by spectrophotometer at 260 nm.
Nonradioactive Northern blot analysis
Ten micrograms of total cellular RNA/lane was size-fractionated by electrophoresis in a 1.2% agarose gel containing 0.7 m formaldehyde, transferred to nylon membranes (Hybond N; Amersham, Arlington Heights, IL, USA) by capillary suction overnight, and crosslinked by UV-light (Stratalinker; Stratagene, La Jolla, CA, USA). The cDNA probe for bcl-2, a 410-bp EcoRI fragment in pCR II Vector (TA cloning vector; Invitrogen, San Diego, CA, USA), digested with BamHI was lab-
Figure 1
Detection 
Patient samples
Genius System (Boehringer Mannheim). Briefly, membranes were washed in buffer 1 (100 mm maleic acid, 150 mm Peripheral blood was drawn from three patients with documented B cell chronic lymphocytic leukemia (B-CLL) 20 after sodium chloride, pH 7.5) for 1 min, followed by a 1 h incubation in buffer 1 containing 1% blocking reagent (buffer 2). informed consent. The isolation of the B-CLL cells was performed using Ficoll-Hypaque gradients (Pharmacia, Piscataway, Membranes were then incubated in buffer 2 containing a 1:10 000 dilution of anti-DIG Fab-fragments, conjugated with NJ, USA). The cells were washed three times in PBS without magnesium chloride and resuspended in RPMI 1640 supalkaline phosphatase (Boehringer Mannheim). Membranes were washed twice for 15 min in buffer 1 containing 0.3% plemented with 10% FBS, 1% penicillin/streptomycin, 1 mM L-glutamine. 1.5 × 10 6 cells/ml were incubated with or withTween 20 (Sigma), followed by an equilibration step in buffer 3 (100 mm Tris-HCl, pH 9.5, 100 mm sodium chloride) for out bFGF (100 ng/ml) for 4 or 8 h at 37°C, 5% CO 2 in air.
]decan]-4-yl)phenyl phosphate (CSPD; Tropix, Bedford, MA, USA) was used as substrate. The Viability stock solution (11.8 mg/ml) was diluted 1:100 in buffer 3. Membranes were incubated for 30 min with diluted CSPD solCell viability was assessed by Trypan blue (Gibco) exclusion using a hemacytometer. At each time-point, samples were colution at 37°C. Substrate solution was removed and membranes were exposed to Cronex 4 film (Du Pont NEN, Boston, lected and each sample was counted in triplicate. The percentage of viable cells in treated samples (fludarabine alone MA, USA) at RT for 2 min to 1 h. or in combination with bFGF) was divided by the average viability control samples at each time-point, respectively.
Actinomycin D experiments
Cells were stimulated with bFGF (10-100 ng/ml) for 8 h before RNA isolation being exposed to actinomycin D (AcD; Sigma) (5 mg/ml). Cells were harvested at intervals of 30, 60, 120 and 180 min Total cellular RNA was prepared as described 21 with some modifications. Briefly, cells were lysed with 0.2 ml of RNAzol poststimulation. A second group enclosed unstimulated cells exposed to AcD in the same time intervals. Cytoplasmatic fat dry milk, and incubated for 30 min in the dark at room temperature. Cells were washed with PBS containing 0.1% RNA was extracted and studied by Northern blot analysis for bcl-2 mRNA expression. Autoradiograms were quantitated by Triton X-100 and resuspended in 0.5 ml PBS containing 5 g/ml propidium iodide (Sigma) and 1 mg/ml RNAse A computer densitometry. In all experiments, data were normalized to the ethidium bromide staining of the 28S ribosomal (Sigma). Green fluorescence detecting FITC levels and red fluorescence measuring propidium iodide content of individ-RNA (rRNA).
ual cells were quantified on a FACStar (Becton Dickinson, Franklin Lakes, NJ, USA), data from 2 × 10 4 cells was collected and used for analysis.
In situ TdT assay
The in situ terminal deoxynucleotidyl transferase (TdT) assay was performed as previously described. 22 Briefly, 2 × 10 6 cells
Western blot analysis were collected from liquid culture, centrifuged and fixed in 0.3% buffered formaldehyde (pH 7.5). After washing with Pellets of 5 × 10 6 cells were resuspended in a lysis buffer containing 20 mm Tris-HCl, 1 mm EGTA, 50 m NaVO 4 , 50 mm PBS, cells were resuspended in 70% ethanol (−20°C) and stored at −20°C. Following rehydration with PBS, the cells NaF, 0.01 U/ml aprotinin, 10 g/ml leupeptin, 1 mm elastinal, 10 g/ml pepstatin, and 1 mm phenyl methyl sulfonyl fluoride were resuspended in 50 l cacodylate buffer containing 0.2 m potassium cacodylate, 2.5 mm Tris-HCl (pH 6.6), 2.5 mm (PMSF) (all Sigma). The lysates were then sonicated using a ultrasonic homogenizer (4710 series; Cole Parmer Instrucobalt chloride (CoCl 2 ), 0.25 mg/ml bovine serum albumin, 7.5 units of terminal deoxynucleotidyl transferase (TdT) and ments, Chicago, IL, USA), centrifuged at 7500 g in a microfuge (Sorvall Instruments, Wilmington, DE, USA), and 0.5 nm biotinylated deoxyuracil-triphosphphate (b-dUTP) (all reagents from Boehringer Mannheim). After an incubation perthe protein content of the lysates was determined (BioRad Protein Assay Kit I; Melville, NY, USA) at 595 nm with a BSA iod in this solution for 30 min at 37°C, cells were washed with PBS and resuspended in 100 l of a solution containing 4× standard. Sample buffer containing 10% glycerol, 0.4% SDS, 0.3% bromphenol blue, 0.2% pyronin Y, in 1× stacking buffer SSC, 25 g/ml avidin-fluorescein-isothiocyanate (avidin-FITC; Boehringer Mannheim), 0.1% Triton X-100 and 5% w/v non-(Tris base 0.5 m, 0.8% SDS), 20% 2-mercaptoethanol, was vival of the cells when exposed to an apoptotic stimulus, JVMpolyacrylamide, and size-fractionated by electrophoresis. Pro-2, JVM-13, I83CLL and WSU-CLL cells were treated with fluteins were electroblotted on to Immobilon-P PVDF transfer darabine alone or in combination with bFGF. Viability, as membrane (Millipore, Bedford, MA, USA) and immunostained determined by Trypan blue exclusion, was performed for each with a mouse anti-human monoclonal bcl-2 antibody (1:5000; cell line, respectively, over a time period of 4 days. ExperiDako, Carpinteria, CA, USA). Bound antibody was detected ments were performed in triplicate. Exposure of JVM-13 to using the ECL chemiluminescence detection system 100 m fludarabine alone resulted in 80% of cells being (Amersham). Protein bands were quantified by computer viable on day 1, 50% on day 2 and 44% by day 3 of culture. densitometry.
After 4 days of culture in the presence of fludarabine alone, only 33% of the cells were still viable ( Table 1 ). The addition of bFGF at 100 ng/ml to JVM-13 resulted in a significant delay Statistical analysis in the decline of viability (P = 0.0087) by day 4 of culture (Table 1 ). In JVM-2 cells treated with fludarabine alone, 46% Student's unpaired, t-test was used to estimate statistical sigand 33% of cells were viable on days 2 and 3, respectively; nificance between the different groups whenever applicable.
in contrast, in JVM-2 cells exposed to fludarabine and bFGF, 74% (P = 0.0166) and 52% (P = 0.0036) were found to be viable on days 2 and 3 of culture. On day 4 of culture, fludaResults rabine-treated JVM-2 cells were found to be only 18% viable, whereas cells exposed to fludarabine and bFGF showed a FGF-receptor expression viability of 38% (P = 0.0213) ( Table 1) . Similarly, protection from fludarabine-induced loss of viability was noted in I83CLL cells ( Table 1 ). The cell lines JVM-2, JVM-13, I83CLL and WSU-CLL were initially examined for the presence of FGF-receptors. As ana-WSU-CLL cells appeared to be more sensitive to fludarabine. Exposure of the cells to 1 m of the drug resulted in 91% lyzed by Northern blotting, all four cell lines were found to express mRNA for the FGF-receptor type 1 (FGFR-1) at viable cells on day 1, 44% on day 2, 51% on day 3, and 37% on day 4. A protective effect of bFGF on the survival of the 4.8 kb (Figure 1) . 71 ± 6 8 5 ± 1 0.0019** 2 9 2 ± 0 4 6 ± 10 74 ± 14 0.0166** 3 9 6 ± 4 3 3 ± 6 5 2 ± 5 0.0036** 4 9 4 ± 1 1 8 ± 4 3 8 ± 2 0.0213** JVM-13 b 1 8 9 ± 4 8 0 ± 2 7 4 ± 7 0.2077 2 9 0 ± 2 5 0 ± 4 4 2 ± 10 0.2479 3 8 9 ± 1 4 4 ± 9 5 3 ± 5 0.2050 4 8 1 ± 1 3 3 ± 9 6 2 ± 6 0.0087** I83CLL b 1 9 5 ± 3 4 7 ± 3 6 8 ± 0 0.0041** 2 9 3 ± 2 1 8 ± 6 2 5 ± 4 0.2032 3 9 7 ± 3 9 ± 6 2 9 ± 4 0.0345** 4 9 4 ± 0 1 1 ± 0 2 0 ± 3 0.0435** WSU-CLL c 1 9 9 ± 1 9 1 ± 3 8 9 ± 1 0.3348 2 9 9 ± 0 4 4 ± 12 66 ± 2 0.0351** 3 9 9 ± 1 5 1 ± 1 7 0 ± 2 0.0068** 4 9 8 ± 2 3 7 ± 3 3 3 ± 10 0. cells treated with both fludarabine and bFGF, could be scripts in all three cell lines ( Figure 3 ). The upregulation of bcl-2 mRNA occurred in a time-dependent manner: in JVMobserved on day 2 and 3 of culture, where 66% (P = 0.0351) and 70% (P = 0.0068) of the cells were viable, respectively 2 an increase of bcl-2 specific transcripts could be detected after 2 h with a maximal mRNA accumulation after 8 h, fol- (Table 1) .
lowed by a decrease to basal expression after 24 h. During the whole period of stimulation, all three transcripts ( 8.5 kb, 6.5 kb and 4.0 kb) were expressed concomitantly. In JVMDelay of fludarabine-induced apoptosis by bFGF 13 bcl-2 mRNA could be induced within a time period of 4 h with a maximal expression after 24 h. A decrease of In order to demonstrate that the decrease in viability in these expression towards basal levels could be observed within the cells was due to fludarabine-induced apoptosis, I83CLL cells next 24 h. This cell line also expressed three bcl-2 specific were treated with fludarabine alone 100 m or with fludarabtranscripts ( Figure 3) . In contrast to JVM-2 and JVM-13, the Bine and bFGF (100 ng/ml) and examined for apoptosis-asso-CLL cell line I83CLL was found to express a single mRNA for ciated DNA strand breaks using the in situ terminal deoxynubcl-2 at 8.5 kb. A significant accumulation of this transcript cleotidyl transferase assay (TdT assay). The intensity of could be observed within 2 h of exposure to bFGF with a labeling of apoptotic cells with biotinylated dUTP correlated maximal expression after 24 h. Transcripts returned to basal with the number of DNA strand breaks per cell. Treatment of levels after a time period of 48 h (Figure 3 ). To further deter-I83CLL cells with fludarabine (100 m) alone for 24 h resulted mine whether the increase of bcl-2 mRNA expression is based in 22.73% cells to be apoptotic; however, in the presence of on post-transcriptional mRNA stabilization by bFGF, we bFGF, only 8.93% of the cells exhibited apoptosis (Figure 2a) . examined the half-life (t 1/2 ) of bcl-2 transcripts in each cell After 48 h of incubation with fludarabine 64% of the cells line. Unstimulated cells or cells pretreated with bFGF were apoptotic, whereas the fraction of apoptotic cells treated (100 ng/ml) were exposed to AcD (5 g/ml) for various time with fludarabine plus bFGF was reduced to 51% (Figure 2b) . intervals. No difference in t 1/2 of bcl-2 mRNA in unstimulated cells compared to cells stimulated with bFGF could be observed (data not shown).
Regulation of bcl-2 mRNA after exposure to bFGF
Regulation of bcl-2 protein upon treatment with bFGF
To evaluate whether the protective effect of bFGF was due to an upregulation of bcl-2, cells were stimulated with bFGF (10 ng/ml) and the expression of bcl-2 mRNA was examined In order to investigate whether the bFGF-induced regulation of bcl-2 mRNA was also reflected on the protein level, we by Northern blot analysis. Both JVM-2 and I83CLL were found to express low amounts of steady-state bcl-2 mRNA, whereas examined cell lysates of the cell lines JVM-2, JVM-13, I83CLL and WSU-CLL for the presence and regulation of bcl-2 protein no bcl-2 transcripts could be detected in unstimulated JVM-13 cells. Kinetic experiments with bFGF during a time period
by Western blot analysis. At baseline JVM-2, I83CLL and WSU-CLL cells were found to express strong bcl-2 protein from 2 to 48 h led to a significant accumulation of bcl-2 tran-
Figure 3
Northern blot analysis of bcl-2 mRNA expression in the human EBV-transformed B prolymphocytic cell lines JVM-2 (a) and JVM-13 (b), and the human EBV-transformed B-CLL cell line I83CLL (c). Total cellular RNA (10 g/lane) of unstimulated cells (0) and cells cultured in the presence of recombinant bFGF (10 ng/ml) for a time period from 2 h to 48 h was hybridized using a digoxigenin-labeled bcl-2 probe. RNA of the human promyelocytic cell line HL-60 was used as control (c). bcl-2-specific transcripts are shown at 8.5 kb, 6.5 kb, and 4.5 kb (JVM-2 and JVM-13) and at 8.5 kb (I83CLL) as indicated by the arrows. The membranes were rehybridized with a digoxigenin-labeled GAPDH probe, respectively. bands; in JVM-13 cells bands of detected bcl-2 protein
The addition of bFGF to JVM-13 cells resulted in a 3-to 4.6-fold increase of bcl-2 protein after 8 h and 24 h, respectively. appeared much weaker. Exposure of bFGF resulted in a marked increase of bcl-2 expression compared to unstimuIn I83CLL cells a 1.7-fold upregulation of bcl-2 protein could be observed after 24 h upon treatment with bFGF. lated cells. Figure 4 shows a representative experiment of the expression of bcl-2 protein in JVM-2, JVM-13 and I83CLL cells Lymphocytes from three patients (P1, P2, P3) with B-CLL were isolated and incubated for 4 or 8 h with or without bFGF after 8 h and 24 h of stimulation. Densitometric analysis of protein bands indicated that bFGF induced a 1.2-fold increase (100 ng/ml). Cell lysates were examined for the regulation of bcl-2 protein using Western blot analysis. The data demonof bcl-2 protein expression in JVM-2 cells after 8 h and 24 h. 18 representative of chronic lymphoid malignancies and (2) that the enhanced bcl-2 expressed in these cells correlates Bcl-2 dependent mechanisms also play a role in the induction of apoptosis, where IL-10 has been shown to enhance with bFGF-mediated protection from fludarabine-induced apoptotic cell death.
spontaneous apoptosis in B-CLL cells by decreasing bcl-2 protein levels. 31 Fludarabine is a drug that has been shown to induce apoptotic cell death in B-CLL cells. 23 We demonstrate here that Delay of apoptosis seems to play an important role in the clonal expansion, tumor progression, and resistance to cytothe addition of exogenous bFGF to fludarabine-treated cells increased the survival of the cells in all three cell lines examtoxic therapy in a number of malignant disorders. 32, 33 In this regard we have also recently extended these observations, ined. The hypothesis that bFGF delays fludarabine-induced apoptosis in CLL cells was confirmed by the TdT assay. The where we have shown that DNA topoisomerase I + II inhibitor-induced apoptosis in K562 chronic myeloid leukemia cells addition of bFGF to fludarabine-treated cells resulted in a reduction of apoptotic cells compared to those treated with (CML) is delayed in response to bFGF. 34 In this study, we demonstrate that basic FGF confers a surfludarabine alone. In this regard, Fuks et al 24 have demonstrated that exogenous bFGF increases the survival of bovine vival advantage to CLL cell lines by delaying their response to an apoptotic stimulus: this likely results in part from an endothelial cells after radiation-induced apoptosis in vitro. 24 Furthermore, bFGF given in vivo to mice, prior to lung upregulation of bcl-2. Increased expression of bcl-2 in CLL has been found frequently; however, the mechanism by which irradiation, resulted in a lower incidence of pneumonitis and lower content of apoptotic cells in tissue samples. 24 An its expression is enhanced is unknown, since specific gene rearrangements appear to be very rare. 14, 35 Other genetic apoptosis delaying effect upon serum starvation has also been shown in cell lines overexpressing bFGF following stable alterations have been reported to be involved in the pathogenesis of CLL. This includes mutations in the tumor suppressor transfection with the gene for bFGF. 40 The bcl-2 protein has been described as a repressor of gene p53 36 and deletions or alterations of the retinoblastoma gene (RB). 37, 38 Whether bFGF acts alone or works in concert apoptosis in many different cell types. 10 Furthermore, it is reported that fludarabine can reduce the expression of bcl-2 with other cytokines in conjunction with these specific genetic alterations involved in the pathogenesis and evolution of mRNA in fresh B-CLL cells in vitro. 25 Our data demonstrate that the protective effect of bFGF against fludarabine-induced CLL 27,29,39 to promote the growth advantage of these malignant cells, remains to be determined and is under investiapoptosis may be mediated by upregulating the expression of bcl-2. In accordance with previously published data, 13, 26 we gation. demonstrated that JVM-2 and I83CLL express low levels of bcl-2 mRNA at steady state. We demonstrate here, for the first time, that bFGF significantly upregulates the expression of bcl
